CN109112154B - Construction method and function verification method of recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 - Google Patents
Construction method and function verification method of recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 Download PDFInfo
- Publication number
- CN109112154B CN109112154B CN201810872978.5A CN201810872978A CN109112154B CN 109112154 B CN109112154 B CN 109112154B CN 201810872978 A CN201810872978 A CN 201810872978A CN 109112154 B CN109112154 B CN 109112154B
- Authority
- CN
- China
- Prior art keywords
- caspase
- gala
- salmonella typhimurium
- recombinant
- vnp20009
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a method for constructing and functionally verifying a Caspase-3 recombinant single-chain antibody, which comprises the following steps: comprises the following steps of (1) constructing pcDNA3.3c-Caspase-3-Gala recombinant plasmid; (2) constructing a pcDNA3.3c-Caspase-3-Gala attenuated salmonella typhimurium VNP20009 recombinant strain; (3) the Caspase-3 recombinant plasmid realizes the eukaryotic expression of the protein Caspase-3 after invading cells by the characteristic of intracellular invasion of attenuated salmonella typhimurium VNP20009, and verifies the killing effect of the protein on the cells. The invention adopts the characteristic of intracellular invasion of the attenuated salmonella typhimurium VNP20009 to realize the expression of the human-derived toxin protein, and simultaneously, a large number of researches show that the attenuated salmonella typhimurium VNP20009 can be specifically gathered in solid tumors, can realize the purpose of specifically killing tumor cells, and provides experimental basis for tumor treatment research.
Description
Technical Field
The invention belongs to the fields of biological pharmacy and tumor medicine, and mainly relates to a method for constructing and functionally verifying a Caspase-3 recombinant single-chain antibody.
Background
Caspase-3 is a key protease in apoptosis of mammalian cells, is in the core position of an apoptosis cascade reaction pathway, and is a necessary pathway of apoptosis protein cascade reaction. Caspase-3 normally exists in the cytoplasm in the form of a proenzyme (32kDa), which is activated during the early stages of apoptosis, and activated Caspase-3 consists of two large (17kDa) and two small (12kDa) subunits, cleaving the corresponding cytoplasmic nuclear substrates, ultimately leading to apoptosis.
The attenuated salmonella typhimurium VNP20009 is used as a treatment vector, the characteristics of intracellular invasion and specific aggregation of the attenuated salmonella typhimurium in solid tumors are comprehensively applied, and the tumor killing specificity is further expanded.
Nowadays, a novel therapeutic Drug of Antibody Drug Conjugates (ADCs) is provided for the clinical treatment of cancer, and the invention provides a certain experimental data basis for the development of ADC Drug treatment by applying the concept and combining with the early-stage basis of an experiment.
Disclosure of Invention
The invention aims to provide an attenuated salmonella typhimurium-mediated plasmid transfection technology in a eukaryotic plasmid expression process.
The second purpose of the invention is to successfully construct a recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009, which has the effect of specifically killing tumor cells.
A construction method of an attenuated salmonella typhimurium mediated human toxin Caspase-3 recombinant single-chain antibody comprises the following steps:
(1) obtaining a Caspase-3-Gala fragment, taking pET302-Caspase-3-Gala as a template and SEQ ID No.3 and SEQ ID No.4 sequences as primers, and carrying out PCR amplification to obtain the Caspase-3-Gala fragment shown in SEQ ID No. 1;
(2) constructing pcDNA3.3c-Caspase-3-Gala recombinant plasmid: connecting the Caspase-3-Gala fragment obtained in the step (1) to pcDNA3.3c by a method of enzyme digestion and enzyme ligation, wherein the sequence of the fragment is as follows: in the plasmid SEQ ID No.2, the recombinant plasmid is named pcDNA3.3c-Caspase-3-Gala;
(3) constructing pcDNA3.3c-Caspase-3-Gala recombinant strain: transferring the pcDNA3.3c-Caspase-3-Gala recombinant plasmid in the step (2) into E.coli Top10 to obtain a recombinant strain;
(4) constructing pcDNA3.3c-Caspase-3-Gala recombinant attenuated Salmonella typhimurium VNP 20009: obtaining a recombinant plasmid from the recombinant strain obtained in the step (3), and then placing the recombinant plasmid into Salmonella typhimurium VNP20009 by an electrotransformation method, wherein the electrotransformation conditions are as follows: 1800V, 25uF, 200 omega and 4.7ms, and the recombined salmonella typhimurium is named pcDNA3.3c-Caspase-3-Gala-VNP 20009.
A recombinant attenuated Salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP 20009.
The method for constructing and functionally verifying the Caspase-3 recombinant single-chain antibody comprises the following steps:
(1) and (3) carrying out mixed culture on the recombinant attenuated salmonella typhimurium VNP20009 obtained in the step 1 and B16F10 cells for 2 hours according to the ratio of the cells to the bacteria of 100:1, and then replacing a fresh culture medium containing the streptomycin to continuously culture for 24 hours.
(2) And (2) respectively carrying out photographing observation on the cells cultured in the step (1) and calculating the specific killing effect of the protein on the cells by adopting an MTT colorimetric method.
The steps adopt the technology of eukaryotic plasmid transfection and expression.
The invention has the beneficial technical effects that:
(1) the attenuated salmonella typhimurium VNP20009 is adopted to mediate eukaryotic plasmid transfected cells to realize eukaryotic expression, and experimental basis is provided for subsequent bacterial treatment means;
(2) the invention utilizes the target specificity of a single-chain antibody and the specific aggregation property of attenuated salmonella typhimurium VNP20009 in solid tumors, combines the cell killing effect of human toxin Caspase-3, belongs to a novel therapeutic drug of an antibody drug conjugate, and can better realize the effect of killing cells by specificity.
Drawings
FIG. 1pcDNA3.3cCaspase-3-Gala PCR validation results, a: Marker-DL2000, b: pcDNA3.3c-Caspase-3-Gala plasmid, c: a Caspase-3-Gala fragment;
FIG. 2 is a microscopic representation of the killing ability of Caspase-3 protein on cells;
FIG. 3 shows the MTT test result of Caspase-3 protein on cell killing ability.
Detailed Description
The original plasmids of the invention are all from Biovector NCTT company.
Coli Top10 and attenuated Salmonella typhimurium VNP20009 of the present invention were purchased from Biovector NCTT.
All restriction enzymes used were purchased from NEB.
The T4DNA ligase used was purchased from Takara.
The DNA ligases used were all purchased from Takara.
Both LB solid medium and liquid medium were purchased from Solebao.
Example 1
And (3) performing PCR amplification by using pET302-Caspase-3-Gala as a template and SEQ ID No.3 and SEQ ID No.4 as primers to obtain a Caspase-3-Gala fragment shown in SEQ ID No. 1.
Example 2
The obtained Caspase-3-Gala fragment and plasmid pcDNA3.3c are double digested by Age I and Bsiw I, the digested products are purified and then connected to pcDNA3.3c (SEQ ID No.2) plasmid by T4 ligase, and the recombinant plasmid is named pcDNA3.3c-Caspase-3-Gala. See the attached figure 1 of the specification.
Example 3
The attenuated salmonella typhimurium VNP20009 preserved at-80 ℃ is streaked and inoculated to an LB plate without resistance and cultured overnight at 37 ℃; picking a single colony in 5ml LB, and carrying out shaking culture at 37 ℃ for 12 h; according to the following steps: inoculating 100 proportion into 100ml LB to shake culture till bacterial OD is about 0.4; after ice-bath for 20min, centrifuging at 4 ℃ and 3000rpm for 10 min; washing thallus precipitate twice with 1/10 volume of precooled sterile deionized water, and centrifuging at 4 ℃ and 3000rpm for 10 min; washing thallus with 1/100 volume precooled 10% glycerol, centrifuging at 4 deg.C 3000rpm for 10 min; the pellet was resuspended in 1/100 volumes of pre-cooled 10% glycerol to make VNP20009 competent aliquots-80 for future use.
Example 4
The obtained recombinant plasmid pcDNA3.3c-Caspase-3-Gala is electrically transferred into an attenuated salmonella typhimurium VNP20009 by adopting a 0.1cm electric transfer cup, and the conditions are as follows: 1.8kv, 200 omega, 25uF, 4.7ms of electric conversion; screening out positive clones through ampicillin resistance to obtain recombinant attenuated salmonella typhimurium VNP20009, which is named pcDNA3.3c-Caspase-3-Gala-VNP 2000.
Example 5
B16F10 cells were seeded in 96-well plates (using penicillin and streptomycin free medium) at 10000/well and recombinant attenuated salmonella typhimurium VNP20009 was seeded at B16F10 cells: recombinant bacteria ═ 100:1 in the total volume of 200 mu L, culturing for 2h, changing to a culture medium containing penicillin and streptomycin, culturing for 24h, and detecting the specific killing effect of the protein on cells by adopting an MTT colorimetric method.
Sequence listing
<110> university of Nanchang
<120> construction method and function verification method of recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009
<130> 2018
<160> 4
<170> SIPOSequenceListing 1 .0
<210> 5
<211> 792
<212> DNA
<213> Artificial sequence (none)
<400> 5
tctggaatat ccctggacaa cagttataaa atggattatc ctgagatggg tttatgtata 60
ataattaata ataagaattt tcataaaagc actggaatga catctcggtc tggtacagat 120
gtcgatgcag caaacctcag ggaaacattc agaaacttga aatatgaagt caggaataaa 180
aatgatctta cacgtgaaga aattgtggaa ttgatgcgtg atgtttctaa agaagatcac 240
agcaaaagga gcagttttgt ttgtgtgctt ctgagccatg gtgaagaagg aataattttt 300
ggaacaaatg gacctgttga cctgaaaaaa ataacaaact ttttcagagg ggatcgttgt 360
agaagtctaa ctggaaaacc caaacttttc attattcagg cctgccgtgg tacagaactg 420
gactgtggca ttgagacaga cagtggtgtt gatgatgaca tggcgtgtca taaaatacca 480
gtggaggccg acttcttgta tgcatactcc acagcacctg gttattattc ttggcgaaat 540
tcaaaggatg gctcctggtt catccagtcg ctttgtgcca tgctgaaaca gtatgccgac 600
aagcttgaat ttatgcacat tcttacccgg gttaaccgaa aggtggcaac agaatttgag 660
tccttttcct ttgacgctac ttttcatgca aagaaacaga ttccatgtat tgtttccatg 720
ctcacaaaag aactctattt ttatcacgga ggtggtggaa gtggaggtgg aggatctgga 780
ggtggaggtt cc 792
<210> 6
<211> 1288
<212> DNA
<213> Artificial sequence (none)
<400> 6
gttaggcgtt ttgcgctgct tcgcgatgta cgggccagat atacgcgttg acattgatta 60
ttgactagtt attaatagta atcaattacg gggtcattag ttcatagccc atatatggag 120
ttccgcgtta cataacttac ggtaaatggc ccgcctggct gaccgcccaa cgacccccgc 180
ccattgacgt caataatgac gtatgttccc atagtaacgc caatagggac tttccattga 240
cgtcaatggg tggagtattt acggtaaact gcccacttgg cagtacatca agtgtatcat 300
atgccaagta cgccccctat tgacgtcaat gacggtaaat ggcccgcctg gcattatgcc 360
cagtacatga ccttatggga ctttcctact tggcagtaca tctacgtatt agtcatcgct 420
attaccatgg tgatgcggtt ttggcagtac atcaatgggc gtggatagcg gtttgactca 480
cggggatttc caagtctcca ccccattgac gtcaatggga gtttgttttg gcaccaaaat 540
caacgggact ttccaaaatg tcgtaacaac tccgccccat tgacgcaaat gggcggtagg 600
cgtgtacggt gggaggtcta tataagcaga gctcgtttag tgaaccgtca gatcgcctgg 660
agacgccatc cacgctgttt tgacctccat agaagacacc gggaccgatc cagcctccgg 720
actctagagg atcgaaccct tactagtgcc accatggagt ttgggctgag ctgggtcttc 780
ctggtggcta tcttgaaggg tgtccagtgt gaggtggcta gcgaattcaa gcttcccggg 840
gtcgacctgc aggagctcct cgagagatct ggatcccacc atcaccacca tcaccaccac 900
gggtgagcgg ccgcttcatg aagggttcga tccctaccgg ttagtaatga gtttaaacgg 960
gggaggctaa ctgaaacacg gaaggagaca ataccggaag gaacccgcgc tatgacggca 1020
ataaaaagac agaataaaac gcacgggtgt tgggtcgttt gttcataaac gcggggttcg 1080
gtcccagggc tggcactctg tcgatacccc accgagaccc cattggggcc aatacgcccg 1140
cgtttcttcc ttttccccac cccacccccc aagttcgggt gaaggcccag ggctcgcagc 1200
caacgtcggg gcggcaggcc ctgccatagc agatctgcgc agctggggct ctagggggta 1260
tccccacgcg ccctgtagcg gcgcatta 1288
<210> 7
<211> 28
<212> DNA
<213> Artificial sequence (none)
<400> 7
ataggctgag agtcggcgac acggccac 28
<210> 8
<211> 29
<212> DNA
<213> Artificial sequence (none)
<400> 8
cgacagagtg ccagccctgg gaccgaacc 29
Claims (2)
1. The construction method of the recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 is characterized by comprising the following steps:
(1) obtaining Caspase-3-Gala fragments: using pET302-Caspase-3-Gala as a template and SEQ ID No.3 and SEQ ID No.4 sequences as primers, and carrying out PCR amplification to obtain a Caspase-3-Gala fragment shown in SEQ ID No. 1;
(2) constructing pcDNA3.3c-Caspase-3-Gala recombinant plasmid: connecting the Caspase-3-Gala fragment obtained in the step (1) to pcDNA3.3c by a method of enzyme digestion and enzyme ligation, wherein the sequence of the fragment is as follows: in the plasmid SEQ ID No.2, the recombinant plasmid is named pcDNA3.3c-Caspase-3-Gala;
(3) constructing pcDNA3.3c-Caspase-3-Gala recombinant strain: transferring the pcDNA3.3c-Caspase-3-Gala recombinant plasmid in the step (2) into E.coli Top10 to obtain a recombinant strain;
(4) constructing pcDNA3.3c-Caspase-3-Gala recombinant attenuated Salmonella typhimurium VNP 20009: obtaining a recombinant plasmid from the recombinant strain obtained in the step (3), and then placing the recombinant plasmid into Salmonella typhimurium VNP20009 by an electrotransformation method, wherein the electrotransformation conditions are as follows: 1800V, 25uF, 200 omega and 4.7ms, and the recombined salmonella typhimurium is named pcDNA3.3c-Caspase-3-Gala-VNP 20009.
2. The functional verification method of the recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 is characterized by comprising the following steps:
(1) the recombinant attenuated salmonella typhimurium VNP20009 of claim 1, which is mixed with B16F10 cells according to the ratio of 100:1 of cells to bacteria for 2 hours, and then replaced by fresh medium containing streptomycin for further culture for 24 hours;
(2) and (2) respectively carrying out photographing observation on the cells cultured in the step (1) and calculating the specific killing effect of the recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 on the cells by adopting an MTT colorimetric method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810872978.5A CN109112154B (en) | 2018-08-02 | 2018-08-02 | Construction method and function verification method of recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810872978.5A CN109112154B (en) | 2018-08-02 | 2018-08-02 | Construction method and function verification method of recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109112154A CN109112154A (en) | 2019-01-01 |
| CN109112154B true CN109112154B (en) | 2021-11-19 |
Family
ID=64852606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810872978.5A Active CN109112154B (en) | 2018-08-02 | 2018-08-02 | Construction method and function verification method of recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109112154B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111088204A (en) * | 2019-12-26 | 2020-05-01 | 南昌大学 | Recombinant escherichia coli expressing Caspase-3 recombinant scFv78 and functional verification method thereof |
| CN110938647A (en) * | 2019-12-26 | 2020-03-31 | 深圳市前海金卓生物技术有限公司 | Recombinant expression vector, recombinant attenuated salmonella typhimurium and construction method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103146626A (en) * | 2013-02-28 | 2013-06-12 | 南京华贞生物医药科技有限公司 | Genetically engineered bacterium for treating breast cancer and construction method and application |
| CN103656684A (en) * | 2013-12-03 | 2014-03-26 | 南京华贞生物医药科技有限公司 | Attenuated salmonella typhimurium and application of genetically engineered bacterium of attenuated salmonella typhimurium to preparation of medicines for treating pancreatic cancer |
| CN105925598A (en) * | 2016-05-13 | 2016-09-07 | 南昌大学 | Preparation method and application of attenuated salmonella typhimurium for secretory expression of GLP-1 (glucagon-like peptide 1) |
-
2018
- 2018-08-02 CN CN201810872978.5A patent/CN109112154B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103146626A (en) * | 2013-02-28 | 2013-06-12 | 南京华贞生物医药科技有限公司 | Genetically engineered bacterium for treating breast cancer and construction method and application |
| CN103656684A (en) * | 2013-12-03 | 2014-03-26 | 南京华贞生物医药科技有限公司 | Attenuated salmonella typhimurium and application of genetically engineered bacterium of attenuated salmonella typhimurium to preparation of medicines for treating pancreatic cancer |
| CN105925598A (en) * | 2016-05-13 | 2016-09-07 | 南昌大学 | Preparation method and application of attenuated salmonella typhimurium for secretory expression of GLP-1 (glucagon-like peptide 1) |
Non-Patent Citations (3)
| Title |
|---|
| GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery;W. Li et al.;《Advanced Drug Delivery Reviews》;20041231;第56卷;第967-985页 * |
| Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies;Michal Bereta et al.;《Vaccine.》;20070522;第25卷(第21期);第4183-4192页 * |
| Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated Salmonella typhimurium using a dual fluorescent live tracking system;Sujin Zhou et al.;《CANCER BIOLOGY & THERAPY》;20161231;第17卷(第7期);第732-740页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109112154A (en) | 2019-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109112154B (en) | Construction method and function verification method of recombinant attenuated salmonella typhimurium pcDNA3.3c-Caspase-3-Gala-VNP20009 | |
| Liu et al. | Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy | |
| Skeate et al. | Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response | |
| TW202014195A (en) | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
| WO2017128534A1 (en) | Method for preparing pd-1/ctla-4 bispecific antibody and use thereof | |
| CN107109362A (en) | Biomolecule is delivered to immunocyte | |
| CN107002090B (en) | Heterologous polypeptide expression cassette | |
| CN107427567A (en) | Checkpoint inhibitor and vaccine combination and its purposes for immunotherapy | |
| WO2022078153A1 (en) | Dna template for modifying primary cell using gene editing, and site-specific insertion method | |
| Ma et al. | Efficacy of targeting SARS-CoV-2 by CAR-NK cells | |
| CN109053894B (en) | Construction method and function verification method of recombinant attenuated salmonella typhimurium | |
| IL293718A (en) | Therapeutic cell compositions and methods for manufacture and uses thereof | |
| Chun et al. | Immune modulation by IL-10 gene transfer via viral vector and plasmid DNA: implication for gene therapy | |
| Miri et al. | CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy | |
| González-Prieto et al. | Rationale redesign of type III secretion systems: toward the development of non-pathogenic E. coli for in vivo delivery of therapeutic payloads | |
| U'ren et al. | Vaccination with liposome–DNA complexes elicits enhanced antitumor immunity | |
| Wan et al. | A single immunization with core–shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs | |
| Ran et al. | Targeting RNA exonuclease XRN1 potentiates efficacy of cancer immunotherapy | |
| Kamensek et al. | Tailor-made fibroblast-specific and antibiotic-free interleukin 12 plasmid for gene electrotransfer-mediated cancer immunotherapy | |
| JP6920786B2 (en) | RNA virus for immunoviral therapy | |
| US11911455B2 (en) | HPV therapeutic nucleic acid vaccine | |
| Connolly et al. | Enhancement of antigen specific humoral immune responses after delivery of a DNA plasmid based vaccine through a contact-independent helium plasma | |
| WO2018101796A1 (en) | Artificial antigen-presenting cell prepared from hla-null cell line by using multiplex crispr-cas9 system and use thereof | |
| US20220265723A1 (en) | Non-viral modification of mesenchymal stem cells | |
| Kuriyama et al. | Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |